$500 Invested in Cronos Group’s (TSX:CRON) IPO Is Worth a Staggering $48,000 Now!

Cronos stock is trading 70% below its record high. Despite this pullback, it has generated multifold returns for early IPO investors.

| More on:
Powder of Cannabis (Drugs), Analysis of Cannabis in laboratory.

Image source: Getty Images

While pot stocks have been impacted by an elongated bear run, early investors have made a fortune. Canadian cannabis stocks rose by an exponential rate right up until recreational marijuana was legalized in the country in October 2018.

Cronos Group (TSX:CRON)(NASDAQ:CRON) has returned a whopping 9,520% since its IPO. The stock was publicly listed at a price of $0.1 per share in July 2014 and has since risen to $9.62 per share. This means if you invested $500 in Cronos Group’s IPO, it would have been worth just over $48,000 as of February 20, 2020.

These returns are really mouth-watering. Now, imagine if you had sold Cronos stock at its record high of $32.6. Your investment of $500 would have returned a massive $163,000 in just under five years. This indicates a total return of 32,500%.

While Cronos has generated astonishing returns, we know it is impossible to time the market. A handful of investors would have bought the stock during IPO and sold at its record high in March 2019.

The important question that needs to be answered is if Cronos stock can continue to generate exponential returns for current investors.

Cronos stock is trading at a high valuation

Cronos stock is currently trading 70% below its 52-week high. The sell-off in the cannabis space was driven by a multitude of reasons. Investors were concerned over sky-high valuations of pot stocks, which prompted the sell-off.

Several companies were then hit by regulatory issues, lower-than-estimated sales, rising losses, high inventory levels, the vaping scandal, and more. Despite the persistent bear run, a few pot companies, including Cronos Group, are trading at expensive multiples.

Cronos stock has a market cap of $3.3 billion and is valued at 91 times forward sales. Analysts expect the company to increase sales by 208.2% to $36 million in 2019 and by 210% to $111.55 million in 2020.

In case Cronos stock doubles by the end of this year, it will be valued at 59 times 2020 sales, which is still an astonishing multiple. Cronos stock, however, has several things going right for it.

What next for investors?

The company is set to grow sales at a stellar pace. It has a cash balance of $2 billion and debt of just $10.54 million. Similar to most marijuana companies, Cronos is struggling to be profitable, but it has enough reserves to sustain top-line growth in the near future.

In late 2018, cigarette giant Altria pumped in $2.4 billion into Cronos for a 45% stake in the company. This was the second-biggest deal in the cannabis space just below Constellation Brands’s US$4 billion investment in Canopy Growth.

Altria’s investment was aimed at growing Cronos Group’s distribution footprint and global infrastructure. Cronos continues to invest heavily in capital expenditures (capex). Its capex has risen from $42.7 million in 2017 to $114 million in 2018. Capex is estimated at $65.7 million in 2019, $67.8 million in 2020, and $97.1 million in 2021, according to consensus forecasts.

Cronos stock has lost significant market value in the last year. Investors can expect pot stocks to be volatile in the short term but the market opportunity and future growth prospects continue to be enticing.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool recommends Constellation BrandsFool contributor Aditya Raghunath has no position in the companies mentioned.

More on Cannabis Stocks

Powder of Cannabis (Drugs), Analysis of Cannabis in laboratory.
Cannabis Stocks

Canopy Growth: Is There Budding Potential in the Cannabis Market?

Canopy Growth stock hit 52-week lows recently on news of needing to re-file on its BIoSteel business, so what now?

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

What’s Happening With Cannabis Stocks in May 2023?

Cannabis stocks were up this week, as the market began to turn, but how long will it last, and is…

Read more »

Cannabis smoke
Cannabis Stocks

Are Cannabis Stocks a Good Buy in May 2023?

If you're going to buy cannabis stocks, these are pretty much the only two I would consider. Even so, you…

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Aurora Cannabis: Time to Light Up Your Portfolio?

Here's my take on whether Aurora Cannabis (TSX:ACB) is worth adding to a growth portfolio right now, given its growth…

Read more »

Target. Stand out from the crowd
Tech Stocks

These Undervalued TSX Stocks Are a Bargain in May 2023

If you're willing to bet on a rebound, these are the three TSX stocks I would consider first as they…

Read more »

A cannabis plant grows.
Cannabis Stocks

Tilray Stock Is Scraping 52-Week Lows: Will it Bottom Out Soon?

Tilray (TSX:TLRY) stock remains down 53% in the last year, but when will this company hit the bottom and start…

Read more »

Medicinal research is conducted on cannabis.
Metals and Mining Stocks

2 Canadian Stocks That Are Simply Too Cheap to Avoid

These two Canadian stocks have sunk lower and lower, which is why now could be the right time for long-term…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

1 Marijuana Stock I’d Buy Over Aurora Cannabis

Explore a promising marijuana stock that outshines Aurora Cannabis. Unveil the investment opportunity to boost your cannabis portfolio.

Read more »